STANDARD VERSUS BIOFILM SUSCEPTIBILITY TESTING IN CYSTIC FIBROSIS (CF)

囊性纤维化 (CF) 的标准与生物膜敏感性测试

• 批准号: 7379332
• 负责人: SAMUEL M MOSKOWITZ
• 金额: $ 0.08万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7379332
• 关键词: STANDARD; VERSUS; BIOFILM; SUSCEPTIBILITY; TESTING

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Many patients with cystic fibrosis (CF) suffer from chronic lung infections punctuated by acute exacerbations. These exacerbations are evidenced by symptoms of increased cough and sputum production, fatigue, weight loss, and dyspnea. Treatment includes antibiotics which may be given orally, intravenously, or by inhalation. To determine which antibiotics are to be prescribed, sputum is cultured to identify bacteria. The most common bacteria in the CF sputa is Pseudomonas aeruginosa. By testing the susceptibility of the bacteria to a variety of antibiotics, a determination can be made as to which antibiotic should be most effective as a treatment. Unfortunately, the effectiveness of this standard susceptibility testing approach is not consistently correlated with clinical response to treatment. This lack of response may be related to the tendency of P. aeruginosa to grow as a biofilm within the airways of CF patients. Biofilms formed by P. aeruginosa laboratory strains generally display marked resistance to the antibiotics commonly used to treat cystic fibrosis. This study will evaluate a new type of susceptibility testing, known as the "biofilm" method.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是中心的机构，不一定是研究者的机构。许多囊性纤维化 (CF) 患者患有慢性肺部感染，并伴有急性加重。这些恶化的症状包括咳嗽和咳痰增加、疲劳、体重减轻和呼吸困难。治疗包括口服、静脉注射或吸入抗生素。为了确定开出哪种抗生素，需要培养痰来鉴定细菌。 CF 痰中最常见的细菌是铜绿假单胞菌。通过测试细菌对各种抗生素的敏感性，可以确定哪种抗生素作为治疗最有效。不幸的是，这种标准药敏试验方法的有效性与治疗的临床反应并不始终相关。这种反应的缺乏可能与铜绿假单胞菌在 CF 患者气道内作为生物膜生长的趋势有关。铜绿假单胞菌实验室菌株形成的生物膜通常对常用于治疗囊性纤维化的抗生素表现出明显的耐药性。这项研究将评估一种新型的敏感性测试，称为“生物膜”方法。